Icon Earnings: Macroeconomic Issues and Trial Delays Affect Our Near-Term View

Narrow-moat Icon is navigating a challenging macroeconomic environment, which has led to elevated cancellation levels due to a range of reasons, including portfolio reprioritizations and futility decisions. Management lowered its 2025 revenue guidance by 5% at the midpoint, which reflects elevated cancellations and the exclusion of two large next-generation covid vaccine trials that had a sponsor-induced delay, and we adjusted our near-term forecast accordingly. We now forecast 2025 revenue of roughly $7.95 billion, a 4% decline year over year. Reflecting this slower near-term growth, we lowered our fair value estimate to $243 per share from $268. However, the stock is trading in 5-star territory, presenting an attractive opportunity for a long-term investor.